Filing Flows › Corcept Therapeutics (CORT) › Q3 2026 › vs Q3 2025
Corcept Therapeutics (CORT) Q3 2026 vs Q3 2025 (year over year)
Corcept Therapeutics's revenue rose $133M (+64%) from $208M in Q3 2025 to $340M in Q3 2026. The biggest changes: Lifyorli +$91.4M (—); Hypercortisolism Products +$41.4M (+20%). Operating margin 33.7% against 4.9% (+28.8 pts).
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 33.7% | 4.9% | +28.8 pts |
| Net margin | 37.2% | 9.5% | +27.8 pts |
| Free cash flow margin | 41.8% | 26.2% | +15.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Hypercortisolism Products | $249M | $208M | $41.4M | +20% |
| Lifyorli | $91.4M | $0 | $91.4M | — |
| Revenue | $340M | $208M | $133M | +64% |
| Other income, net | $5.6M | $5.0M | $559K | +11% |
| Operating profit | $115M | $10.2M | $105M | 11× |
| Costs & expenses | $226M | $197M | $28.3M | +14% |
| Pre-tax earnings | $120M | $15.2M | $105M | +689% |
| Cost of revenue | $4.6M | $4.6M | $12K | +0.3% |
| Research & development | $56.7M | $68.8M | −$12.1M | -18% |
| SG&A | $164M | $124M | $40.5M | +33% |
| Income tax benefit | $6.5M | $4.4M | $2.0M | +46% |
| Net earnings | $127M | $19.7M | $107M | +545% |
| Depreciation & amortization | $1.0M | $477K | $549K | +115% |
| Share-based compensation | $29.4M | $22.9M | $6.6M | +29% |
| Working capital & other | $14.4M | −$11.5M | $25.8M | — |
| Operating cash flow | $143M | $54.5M | $88.4M | +162% |
| Free cash flow (OCF − capex) | $142M | $54.5M | $87.7M | +161% |
| Capital expenditures | $709K | $0 | $709K | — |
Questions
How much did Corcept Therapeutics's revenue grow year over year in Q3 2026?
Corcept Therapeutics's revenue rose $133M (+64%) from $208M in Q3 2025 to $340M in Q3 2026.
What drove Corcept Therapeutics's revenue change in Q3 2026?
Lifyorli +$91.4M (—); Hypercortisolism Products +$41.4M (+20%).